Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Lindbrook Capital LLC

Lindbrook Capital LLC increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 28.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,570 shares of the medical equipment provider’s stock after buying an additional 344 shares during the period. Lindbrook Capital LLC’s holdings in Zimmer Biomet were worth $191,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in ZBH. Schechter Investment Advisors LLC raised its holdings in shares of Zimmer Biomet by 21.6% in the 3rd quarter. Schechter Investment Advisors LLC now owns 4,241 shares of the medical equipment provider’s stock valued at $476,000 after purchasing an additional 752 shares in the last quarter. Atria Wealth Solutions Inc. lifted its holdings in Zimmer Biomet by 5.9% during the 3rd quarter. Atria Wealth Solutions Inc. now owns 20,566 shares of the medical equipment provider’s stock worth $2,312,000 after buying an additional 1,144 shares during the last quarter. International Assets Investment Management LLC boosted its position in shares of Zimmer Biomet by 11,244.9% during the 4th quarter. International Assets Investment Management LLC now owns 66,935 shares of the medical equipment provider’s stock worth $8,146,000 after acquiring an additional 66,345 shares in the last quarter. Amalgamated Bank increased its holdings in shares of Zimmer Biomet by 3.0% in the 3rd quarter. Amalgamated Bank now owns 56,166 shares of the medical equipment provider’s stock valued at $6,303,000 after acquiring an additional 1,631 shares during the last quarter. Finally, Sequoia Financial Advisors LLC raised its position in shares of Zimmer Biomet by 37.5% during the 4th quarter. Sequoia Financial Advisors LLC now owns 155,965 shares of the medical equipment provider’s stock worth $18,981,000 after acquiring an additional 42,539 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 1.1 %

NYSE:ZBH opened at $120.78 on Tuesday. The stock has a market capitalization of $24.82 billion, a price-to-earnings ratio of 24.70, a PEG ratio of 2.19 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a 1 year low of $102.00 and a 1 year high of $149.25. The stock has a fifty day moving average price of $126.23 and a two-hundred day moving average price of $119.37. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The business had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. During the same quarter last year, the firm posted $1.88 EPS. The business’s revenue was up 6.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.79%. The ex-dividend date is Wednesday, March 27th. Zimmer Biomet’s payout ratio is currently 19.63%.

Insider Buying and Selling

In other news, VP Chad F. Phipps sold 26,156 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the transaction, the vice president now owns 44,145 shares in the company, valued at $5,677,929.90. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.70% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ZBH shares. Evercore ISI increased their price target on shares of Zimmer Biomet from $125.00 to $130.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Barclays boosted their price target on shares of Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a research report on Monday, February 12th. StockNews.com lowered Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a report on Monday, February 19th. Canaccord Genuity Group reissued a “hold” rating and issued a $130.00 target price on shares of Zimmer Biomet in a report on Friday, February 23rd. Finally, Raymond James lifted their price target on Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $139.39.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.